We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation
2025-07-15 Interview with Redeye

2025-07-15 Interview with Redeye

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical

Watch the interview here

2025-06-11 Redeye Investor Forum, Stockholm

Interim CEO Damian Marron presents at Redeye Investor Forum, Stockholm

Watch the presentation here
2025-06-11 Redeye Investor Forum, Stockholm

2025-03-26 Interview with H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

2025-03-26 Interview with H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Interview with Interim CEO Damian Marron during the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Watch the interview here

2025-02-07 Interview with Redeye

Interview with Interim CEO Damian Marron

Watch the interview here
2025-02-07 Interview with Redeye


Current corporate presentation

Download the corporate presentation as PDF